Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Yoshihito UchidaKayoko NaikiJun-Ichi KouyamaKayoko SugawaraMasamitsu NakaoDaisuke MotoyaMie InaoNobuaki NakayamaYukinori ImaiTomoaki TomiyaSatoshi MochidaPublished in: PloS one (2018)
High serum concentrations of serum asunaprevir, which were associated with the extent of liver fibrosis, appear to provoke the occurrence of liver injury in patients with genotype-1b HCV receiving combined daclatasvir plus asunaprevir therapy.